Stromectol
- Be greater than in those at lower risk. Using a combination of acquisition costs and effectiveness to assess the cost effectiveness of prevention in patients with established osteoporosis, Francis et al 1995 ; estimated that treatments with the lowest acquisition cost were most cost effective; however, it is possible that more expensive therapies may be more cost effective if the side-effect profile and or follow-on costs are favourable. Nevertheless, an example of an intervention which is likely to be highly cost-effective in patients with established osteoporosis i.e. those who have sustained a hip fracture ; is the use of hip protectors. For a 78 year old woman with a history of hip fracture, the relative risk of a second hip fracture is increased six-fold Schroder et al, 1993 ; , equivalent to an absolute risk of fracture in the next year of around 7%. Assuming that hip protectors cost 75 UK sterling ; per woman and prevent 50% of hip fractures Lauritzen et al, 1993; Ekman et al, 1997 ; this will cost only 2143 per hip fracture averted, which is much less than the acute hospital cost of treating a second fracture French et al, 1995 ; . Given that second hip fractures account for about 10% of hip fracture admissions, the use of hip protectors would reduce the overall number of hip fractures by 5%, assuming 50% efficacy as above ; . 5.3.7 Conclusions. Effective pharmacological interventions are available for the treatment of women with postmenopausal osteoporosis. Increases in bone mineral are not necessarily associated with increased resistance of the skeleton to fractures and documentation of lack of adverse effects of any new agent on bone quality in animal models is therefore mandatory before proceeding with clinical studies. In addition, recent preliminary analyses of large trials have revealed that the reduction in fracture frequency by inhibitors of bone turnover is much greater than would be expected from the observed changes in bone mass. Clinicians confronted with the individual patient are now in a much better position than only a few years ago, when therapeutic decisions were based exclusively on experience, intuition and extrapolation of data. Adequate knowledge, however, of the advantages and disadvantages of pharmacological interventions is essential and should be applied together with other measures which can improve bone health, reduce patients's complaints and risks and improve their quality of life. Evaluation of the economic costs of osteoporosis prevention have so far been based on modelling studies related to the use of HRT. Further research is required to establish the quality of life effects of different treatments of osteoporosis and to generate cost data from randomised trials. In addition, relatively inexpensive preventive strategies such as hip protectors, vitamin D and HRT warrant further economic evaluation, using simple economic modelling Torgerson et al, 1996c.
1. rlefors H, Sundin A, Garske U, Juhlin C, berg K, Skogseid B, Lngstrm B, Bergstrm M, Eriksson B. Whole-Body 11C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography. J Clin Endocrinol Metabol 2005; 90: 3392-3400. Uchino H, Kanai Y, Kim D, Wempe M, Chairoungdua A, Morimoto E, Anders MW, Endou H. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 LAT1 ; : insights into the mechanisms of substrate recognition. Mol Pharmacol 2002; 61: 729-737. De Vries E, Luurtsema G, Brussermann M, Elsinga P, Vaalburg W. Fully automated synthesis module for the high yield one-pot preparation of 6[18F]fluoro-L-DOPA. Appl Radiat Isot 1999; 51: 389-394. Sundin A, Eriksson B, Bergstrm M, Bjurling P, Lindner K, berg K, Lngstrm B. Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. Nucl Med Biol 2000; 27: 33-41.
Treatment Treatment consists of application to the whole body except the head and neck. Follow directions on medication bottle ; with either of these products: One percent 1% ; gamma benzene hexachloride lindane, Kwell ; Crotamiton Eurax ; Emulsion of benzyl benzoate On the next day, a cleansing bath is taken and a change made to fresh clothing and bedclothes. Itching may persist for 1-2 weeks and during this period should not be regarded as a sign of drug failure or reinfestation ; . Over treatment is common and should be avoided because of toxicity of some of these agents, especially gamma benzene hexachloride Kwell ; . Ivermectin Stromecol ; is related to macrolide antibiotics; it was developed in the 1970s as a veterinary treatment for animal parasites. Ivermectin also has been used to treat animal scabies, which causes mange. Ivermectin has been used in humans to treat millions of cases of onchocerciasis, other filariases and intestinal nematodal infections such as strongyloidiasis. In 1993, a study comparing oral ivermectin with topical 10 percent benzyl benzoate found that absolute results favored the use of ivermectin, but the difference was not statistically significant. Studies in Africa and India have suggested that an effective dosage of ivermectin is 200 g per kg. Ivermectin seems to be concentrated in the liver and fat tissue, with very low levels reaching the central nervous system. No significant drug interactions have been reported. Ivermectin is not approved for treatment of scabies by the U.S. Food and Drug Administration. There are concerns regarding its use in young children and pregnant women, because there may be more drug penetrance of the immature blood-brain barrier. Although standard topical treatment of scabies is effective in many patients, there may be a particular role for oral ivermectin in refractory infestations or when compliance with head-to-toe application of topical agents is logistically difficult e.g., large institutional outbreaks or mentally impaired patients ; . Immunocompromised patients with crusted scabies have very high parasite loads and also may benefit from oral treatment. Some authors recommend concomitant oral and topical treatment because systemic medication may not effectively penetrate thick, crusted areas. Topical formulations of ivermectin also exist but have been less widely studied.Rossetto M, Gross CL, Jones R, Hunter J 2004a ; The impact of clonality on an endangered tree Elaeocarpus williamsianus ; in fragmented rainforest. Biological Conservation 117, 33-39. Rossetto M, Jones R, Hunter J 2004b ; Genetic effects of rainforest fragmentation in an early successional tree Elaeocarpus grandis ; . Heredity 93, 610-619. Williams GA 1993 ; Hidden rainforests: Subtropical rainforest and their invertebrate biodiversity. UNSW Press: Sydney ; Williams GA 2002 ; A taxonomic and biogeographic review of the invertebrates of the Central Eastern Rainforest Reserves of Australia CERRA ; World Heritage Area and adjacent regions. Technical Reports of the Australian Museum 16.
DRUG NAME VECTIBIX ANTINEOPLASTIC HUM VEGF INHIBITOR AVASTIN ANTI-PARASITICS DRUGS FOR WORM SCABIES, ETC. TREATMENT ANTIPARASITICS, ANTHELMINTICS ALINIA mebendazole MINTEZOL STROMECTOL ANTIPARASITICS, ANTIPROTOZOALS chloroquine DARAPRIM FANSIDAR hydroxychloroquine MALARONE mefloquine PRIMAQUINE QUALAQUIN TINDAMAX ANTIPARASITICS, PEDICULICIDES SCABI CIDES.The terms "relate, " "related, " "relating, " or "regarding" as to any given subject means anything that discusses, concerns, reflects, constitutes, contains, embodies, identifies, deals with, or is any manner whatsoever pertinent to that subject, including but not limited to documents concerning the preparation of other documents. The terms "and" and "or" shall be construed broadly and either conjunctively or disjunctively to bring within the scope of this document request any information which might otherwise be construed to be outside its scope. The singular includes plural number, and vice versa to bring within the scope of this document request any information which might otherwise be construed to be outside its scope. The masculine includes the feminine and neuter genders to bring within the scope of this document request any information that might otherwise be construed to be outside its scope. The term "communication" means each manner or means of disclosure or exchange of information, regardless of means utilized, whether oral, written, electronic, by document or otherwise, and whether face to face, in a meeting, by telephone, mail, telexes, discussions, releases, personal delivery, or otherwise. Documents that typically reflect a "communication" include handwritten notes, telephone memoranda slips, daily appointment books and diaries, bills, checks, correspondence and memoranda, and includes all drafts of such documents and vantin. The form requires examples of recent behaviors which have been directly observed by the person filling out the form, and why the individual needs to be hospitalized. See Section 401 criteria on previous page. ; The form must also include the names and addresses of witnesses and the name and address of the person's nearest relative, guardian or friend. The form may be obtained through Probate Court or your local Community Mental Health Services Program. See Appendix B. ; A physician or clinical psychologist will examine the individual. If the doctor finds that the individual meets the criteria for admission, he she will fill out a Clinical Certificate stating that the person examined requires treatment. The individual will then be admitted to a hospital and a second assessment and Clinical Certificate will be completed by a psychiatrist. If the mental health professional who conducts the preadmission screening denies hospitalization, the relative or other involved person may request a second opinion and an additional evaluation will be performed as soon as possible. Within 72 hours of admission, excluding Sundays and holidays, the individual will have a deferral meeting in the hospital and be assigned representation by a lawyer. The patient may also designate a friend or relative to attend. At this meeting, a representative from the Community Mental Health Services Program and one from the hospital will present a proposed treatment plan. If the person agrees to cooperate with this plan, he she is accepted as a voluntary patient. However, if at any time during the course of treatment the person refuses to accept the agreed-on treatment, the hospital may notify the Probate Court and a court hearing will be held on the original application. The hearing will be held within 7 days of the date that all necessary forms are received by the Probate Court. It will be necessary for the individual who signed the application to be in court in order to testify about the person's behavior. Admission by petition. A Petition for hospitalization requires the same form Petition Application form ; and information as for admission by Clinical Certification described above. The main difference between the two procedures is that the Petition is filed directly with the Probate Court. A Clinical Certificate should accompany the petition, but if it is not possible to obtain one, the Probate Court can order by police transport if necessary ; the person to be examined by a psychiatrist and either another physician or a clinical. Months after the dose, respectively. A marked reduction of 90% was maintained for up to 12 months after the single dose. As with other microfilaricidal drugs, there was an increase in the microfilariae count in the anterior chamber of the eye at day 3 after treatment in some patients. However, at 3 and 6 months after the dose, a significantly greater percentage of patients treated with STROMECTOL had decreases in microfilariae count in the anterior chamber than patients treated with placebo. In a separate open study involving pediatric patients ages 6 to 13 103; weight range: 17-41 kg ; , similar decreases in skin microfilariae counts were observed for up to 12 months after dosing. INDICATIONS AND USAGE STROMECTOL is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract. STROMECTOL is indicated for the treatment of intestinal i.e., nondisseminated ; strongyloidiasis due to the nematode parasite Strongyloides stercoralis. This indication is based on clinical studies of both comparative and open-label designs, in which from 64-100% of infected patients were cured following a single 200-g kg dose of ivermectin. See CLINICAL PHARMACOLOGY, Clinical Studies. ; Onchocerciasis. STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus. This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate DEC-C ; . NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules nodulectomy ; may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites. CONTRAINDICATIONS STROMECTOL is contraindicated in patients who are hypersensitive to any component of this product. WARNINGS Historical data have shown that microfilaricidal drugs, such as diethylcarbamazine citrate DEC-C ; , might cause cutaneous and or systemic reactions of varying severity the Mazzotti reaction ; and ophthalmological reactions in patients with onchocerciasis. These reactions are probably due to allergic and inflammatory responses to the death of microfilariae. Patients treated with STROMECTOL for onchocerciasis may experience these reactions in addition to clinical adverse reactions possibly, probably, or definitely related to the drug itself. See ADVERSE REACTIONS, Onchocerciasis. ; The treatment of severe Mazzotti reactions has not been subjected to controlled clinical trials. Oral hydration, recumbency, intravenous normal saline, and or parenteral corticosteroids have been used to treat postural hypotension. Antihistamines and or aspirin have been used for most mild to moderate cases. PRECAUTIONS General After treatment with microfilaricidal drugs, patients with hyperreactive onchodermatitis sowda ; may be more likely than others to experience severe adverse reactions, especially edema and aggravation of onchodermatitis. Rarely, patients with onchocerciasis who are also heavily infected with Loa loa may develop a serious or even fatal encephalopathy either spontaneously or following treatment with an effective microfilaricide. In these patients, the following adverse experiences have also been reported: back pain, conjunctival hemorrhage, dyspnea, urinary and or fecal incontinence, difficulty in standing, mental status changes, confusion, lethargy, stupor, or coma. This syndrome has been seen very rarely following the use of and zyvox. Anthelmintics ALBENZA TAB 200mg Albendazole ; BILTRICIDE TAB 600mg Praziquantel ; mebendazole chew tab 100 mg MINTEZOL CHW 500mg Thiabendazole ; MINTEZOL SUS 500 5ml Thiabendazole ; STROMECTOL TAB 3mg Ivermectin ; STROMECTOL TAB 6mg Ivermectin ; Antibacterials Aminoglycosides amikacin sulfate inj 250 mg ml amikacin sulfate inj 50 mg ml AMIKIN INJ 100 2ml Amikacin Sulfate ; AMIKIN INJ 1GM 4ml Amikacin Sulfate ; gentamicin in saline inj 0.6 mg ml gentamicin in saline inj 0.8 mg ml gentamicin in saline inj 0.9 mg ml gentamicin in saline inj 1 mg ml gentamicin in saline inj 1.2 mg ml gentamicin in saline inj 1.4 mg ml gentamicin in saline inj 1.6 mg ml gentamicin sulfate inj 40 mg ml gentamicin sulfate iv soln 10 mg ml kanamycin sulfate inj 333 mg ml NEO-FRADIN SOL 125 5ml Neomycin Sulfate ; neomycin sulfate tab 500 mg tobramycin sulfate for inj 1.2 gm tobramycin sulfate inj 0.8 mg ml in saline tobramycin sulfate inj 1.2 mg ml in saline tobramycin sulfate inj 10 mg ml tobramycin sulfate inj 40 mg ml Cephalosporins CEDAX CAP 400mg Ceftibuten ; CEDAX SUS 90mg 5ml Ceftibuten ; cefaclor cap 250 mg cefaclor cap 500 mg cefaclor for susp 125 mg 5ml cefaclor for susp 250 mg 5ml cefaclor for susp 375 mg 5ml cefaclor monohydrate tab sr 12hr 500 mg cefadroxil cap 500 mg 5 2. Announced the decision to submit a rolling new drug application nda ; to market rsr13 as an adjunct to whole brain radiation therapy for the treatment of brain metastases from breast cancer and myambutol. Were stated to be double-blind, but only in Pope 199148 was it clear from the report that participants, investigators and outcome assessors were blind to treatment group. ITT analysis was carried out in the Kowatch 200054 and McElroy 199655 but not in the Bowden 199449 and Pope 199148 trials. It was unclear whether ITT analysis was carried out in the Hirschfeld 199953 trial. The dose of comparator drug given seemed to be appropriate in all five RCTs. More than a million babies around the world have now been born as a result of assisted conception treatment such as IVF and the chances are you will give birth to a healthy baby. But as well as huge benefits, all medical treatments carry some risks. There is no way of ruling out the slight chance of problems, no matter how the baby was conceived, and most problems are relatively minor. You may find it hard, but try to relax and enjoy your pregnancy if you possibly can. You have come on a long journey and now you are about to set out on another and isoniazid. 33. Like the majority, I use ``Zeneca'' to refer collectively to defendants Zeneca, Inc., Astrazeneca Pharmaceuticals LP, and AstraZ.
Order generic Stromecgol online
Albendazole - Albenza GlaxoSmithKline ; artemether - Artenam Arenco, Belgium ; artesunate - Guilin No. 1 Factory, People's Republic of China ; atovaquone - Mepron GlaxoSmithKline ; atovaquone proguanil -- Malarone GlaxoSmithKline ; bacitracin - many manufacturers bacitracin-zinc - Apothekernes Laboratorium A.S., Oslo, Norway ; benznidazole - Rochagan Roche, Brazil ; bithionol - Bitin Tanabe, Japan ; chloroquine HCl and chloroquine phosphate - Aralen Sanofi ; , others crotamiton - Eurax Westwood-Squibb ; dapsone - Jacobus ; diethylcarbamazine citrate USP - University of Iowa School of Pharmacy ; diloxanide furoate - Furamide Boots, United Kingdom ; eflornithine Difluoromethylornithine, DFMO ; - Ornidyl Aventis ; furazolidone - Furoxone Roberts ; halofantrine - Halfan GlaxoSmithKline ; iodoquinol - Yodoxin Glenwood ; , others ivermectin - Sttromectol Merck ; malathion - Ovide Medicis ; mebendazole - Vermox McNeil ; mefloquine - Lariam Roche ; meglumine antimonate - Glucantime Aventis, France ; melarsoprol - Mel-B Specia ; * metronidazole - Flagyl Searle ; , others miltefosine - Zentaris ; niclosamide - Yomesan Bayer, Germany ; nifurtimox - Lampit Bayer, Germany ; nitazoxanide - Cryptaz Romark ; ornidazole - Tiberal Roche, France ; oxamniquine - Vansil Pfizer ; paromomycin - Humatin Monarch Leshcutan Teva Pharmaceutical Industries, Ltd., Israel; topical formulation not available in US ; pentamidine isethionate - Pentam 300, NebuPent Fujisawa ; permethrin - Nix GlaxoSmithKline ; , Elimite Allergan ; praziquantel - Biltricide Bayer ; primaquine phosphate USP proguanil - Paludrine Wyeth Ayerst, Canada; AstraZeneca, United Kingdom in combination with atovaquone as Malarone GlaxoSmithKline ; propamidine isethionate - Brolene Aventis, Canada ; pyrantel pamoate - Antiminth Pfizer ; pyrethrins and piperonyl butoxide - RID Pfizer ; , others pyrimethamine USP - Daraprim GlaxoSmithKline ; quinine dihydrochloride quinine sulfate - many manufacturers sodium stibogluconate - Pentostam GlaxoSmithKline, United Kingdom ; spiramycin - Rovamycine Aventis ; suramin sodium - Bayer, Germany ; thiabendazole - Mintezol Merck ; tinidazole - Fasigyn Pfizer ; triclabendazole - Egaten Novartis, Switzerland ; trimetrexate - Neutrexin US Bioscience and cleocin.
Index of Covered Drugs RITUXAN 10 mg ml CONCENTRATE, INTRAVENOUS. 34 ROFERON-A 3, 000, 000 UNIT 0.5 ml SUBCUTANEOUS KIT. 35 ROFERON-A SUBCUTANEOUS . 35 romycin 5 mg g eye ointment . 70 ROTATEQ VACCINE 2 ml ORAL SUSPENSION . 66 roxanol concentrate 20 mg ml oral . 22 roxicet 5 mg-325 mg 5 ml oral solution. 22 roxicet oral . 22 roxicodone 5 mg 5 ml oral solution. 22 roxicodone intensol 20 mg ml oral concentrate . 22 roxicodone oral. 22 S salsalate oral . 22 SANCTURA 20 mg TABLET . 60 SANTYL 250 UNIT G OINTMENT. 56 selegiline hcl oral. 38 selenium sulfide 2.5 % shampoo . 56 SELZENTRY ORAL . 39 SEMPREX-D 8 mg-60 mg CAPSULE. 72 SENSIPAR ORAL . 71 SEROMYCIN 250 mg CAPSULE. 28 SEROQUEL ORAL . 38 SEROQUEL XR ORAL . 38 SEROSTIM SUBCUTANEOUS . 64 sertraline oral. 31 silver sulfadiazine 1 % topical cream. 56 SIMULECT INTRAVENOUS67 simvastatin oral . 47 SINGULAIR ORAL. 73 sodium bicarbonate intravenous .78 sodium chloride 0.45 % intravenous.78 sodium chloride 0.9 % intravenous.78 sodium chloride 0.9 % irrigation solution .76 sodium chloride 5 % intravenous .78 sodium chloride intravenous.78 sodium lactate intravenous .78 sodium polystyrene sulfonate oral.75 sodium polystyrene sulfonate rectal .75 SOLARAZE 3 % TOPICAL GEL .35 solia 0.15 mg-30 mcg tablet .61 SOLTAMOX 10 mg 5 ml ORAL SOLUTION.62 SORIATANE ORAL .56 sotalol af oral .49 sotalol oral .49 sotret oral.55 SPIRIVA WITH HANDIHALER 18 MCG & INHALATION CAPSULES72 spironolactone oral.52 spironolacton-hydrochlorothiaz 25 mg-25 mg tablet .52 sprintec 28 ; 0.25 mg-35 mcg tablet .61 SPRYCEL ORAL .35 starlix oral.42 STRATTERA ORAL.53 streptomycin 1 gram intramuscular .24 STROMECTOL ORAL .37 SUBOXONE 8 mg BUPRENORPHINE WITH 2 mg NALOXONE TABLET22 SUCRAID 8, 500 UNIT ml ORAL SOLUTION.58 sucralfate 1 gram tablet .59 sulfacetamide sodium acne ; 10 % topical suspension .55 sulfacetamide sodium 10 % eye drops. 70 sulfacetamide sodium 10 % eye ointment . 70 sulfacetamide-prednisolone 10 %-0.25 % eye drops. 70 sulfadiazine 500 mg tablet . 26 sulfasalazine oral . 26 sulfatrim 40 mg-200 mg 5 ml oral suspension . 26 sulfazine 500 mg tablet. 26 sulfazine enteric coated 500 mg tablet. 26 sulindac oral . 20 SUSTIVA ORAL . 39 SUTENT ORAL. 35 SYMLIN 600 MCG ml SUBCUTANEOUS . 41 SYNAGIS INTRAMUSCULAR . 39 SYNAREL 2 mg ml NASAL SPRAY AEROSOL . 36 SYNTHROID ORAL . 63 SYPRINE 250 mg CAPSULE78 T TAMIFLU 12 mg ml ORAL SUSPENSION. 39 TAMIFLU ORAL . 39 tamoxifen oral . 62 TARCEVA ORAL . 35 TARGRETIN 1 % TOPICAL GEL. 36 TARGRETIN 75 mg CAPSULE . 35 TARKA ORAL . 47 taxol 6 mg ml concentrate, intravenous . 36 TAXOTERE INTRAVENOUS . 36 TAZORAC TOPICAL. 56 taztia xt oral. 51 TEGRETOL XR ORAL . 29 terazosin oral . 48 terbinafine 250 mg tablet . 32 terbutaline injection . 73 terbutaline oral. 73 terconazole vaginal . 32 16.
Soffban 7224 BV ; .Repatriation Schedule .501 Sofradex AV ; .307 Soframycin AV ; .307 SofTact MS ; .310 Solavert AW ; .108 Solian 100 SW ; .269 Solian 200 SW ; .269 Solian 400 SW ; .269 Solian Solution SW ; .269 Solone FM ; .154 SoloSite Gel 36361338 SN ; .Repatriation Schedule .510 Solprin RC ; .Blood and blood forming organs .101 ntal.353 .Nervous system .257 SoluCortef PH ; ntal.335 .Doctor's Bag Supplies .69 .Systemic hormonal preparations, excl. sex hormones and insulins .154 Solugel 10336 JJ ; .Repatriation Schedule .510 SoluMedrol PF ; .154 Somac PH ; . 81, 82 SOMATROPIN Recombinant human growth hormone ; ction 100 .424 Somatuline Autogel IS ; ction 100 .412 Somatuline LA IS ; ction 100 .411 Sone FM ; .155 Sorbidin AF ; .110 SORBITOL with SODIUM CITRATE and SODIUM LAURYL SULFOACETATE .Alimentary tract and metabolism.88 .Palliative Care.323 .Repatriation Schedule .474 Sorbsan 1410 UM ; .Repatriation Schedule .505 Sorbsan 1411 UM ; .Repatriation Schedule .504 Sotab DP ; .108 Sotacor BQ ; .108 Sotahexal HX ; .108 SOTALOL HYDROCHLORIDE.108 SOY PROTEIN and FAT FORMULA with VITAMINS and MINERALS--CARBOHYDRATE FREE .318 SpanK AS ; .98 Spenco Dermal Pad 10553 KC ; .Repatriation Schedule .512 Spenco Dermal Pad 10561 KC ; .Repatriation Schedule .512 Spiractin 25 AF ; .114 Spiractin 100 AF ; .114 Spiriva BY ; .297 SPIRONOLACTONE.114 Sporahexal HX ; .Antiinfectives for systemic use .164 ntal.341 Sporanox JC ; . 174 Stalevo 50 12.5 200mg NV ; . 266 Stalevo 100 25 200mg NV ; . 266 Stalevo 150 37.5 200mg NV ; . 266 Staphylex 250 AF ; .Antiinfectives for systemic use . 162 ntal . 339 Staphylex 500 AF ; .Antiinfectives for systemic use . 162 ntal . 340 STAVUDINE ction 100 . 421 Stelax 10 AW ; . 242 Stelax 25 AW ; . 242 Stelazine LM ; . 267 Stemetil AV ; .Alimentary tract and metabolism . 85, 86 ntal . 333 .Doctor's Bag Supplies . 70 Stemzine HP ; .Alimentary tract and metabolism . 85 ntal . 333 STERCULIA with FRANGULA BARK .Alimentary tract and metabolism . 87 .Palliative Care. 322 .Repatriation Schedule . 474 Steripaste 3610 SS ; .Repatriation Schedule . 504 Stieprox Liquid SX ; .Repatriation Schedule . 478 Stocrin MK ; ction 100 . 375 Stdomectol MK ; . 290 Suboxone RC ; ction 100 . 427 Subutex RC ; ction 100 . 427 SUCRALFATE . 83 Sudafed Sinus &Nasal Decongestant PC ; .Repatriation Schedule . 496 SULFACETAMIDE SODIUM. 300 SULFASALAZINE. 91 SULINDAC ntal . 347 .Musculoskeletal system . 238 .Palliative Care. 326 SULTHIAME . 264 SUMATRIPTAN . 259 SUMATRIPTAN SUCCINATE . 259 SUNSCREENS .Repatriation Schedule . 479 SunSense Cream SPF30 + EO ; .Repatriation Schedule . 479 SunSense Ultra SPF30 + EO ; .Repatriation Schedule . 480 Surepress 650947 CC ; .Repatriation Schedule . 501 Surepress 650948 CC ; .Repatriation Schedule . 501 Surgam AV ; . 240 and minocin. And or unstable graft function due to ongoing immunemediated events 25 ; . One insulin independent subject, required reintroduction of insulin again at 303 days postsupplemental infusion and remains euglycemic on Lantus 810 U daily. Supplemental infusions were precluded in three subjects Hypereosinophilic syndrome HES ; n 1, lost to follow-up n 1, voluntary withdrawal n 1 ; . mean follow-up of 33 6 months, eleven subjects remain on immunosuppression, eight of whom are insulin independent 73% ; , two of these with supplemental infuAmerican Journal of Transplantation 2005; 5: 20372046. Even though the immune system defends the body against disease, it is also susceptible to disease Table 11-10 ; . The body can also produce antibodies immunity ; against its own auto ; normal tissue. Two autoimmune diseases are rheumatoid arthritis and lupus erythematosus. Varied symptoms can occur, such as joint pain, skin rash, and fever and tetracycline.What is TYSABRI? TYSABRI is a prescription medicine approved for patients with relapsing forms of MS to: -- Slow the worsening of disability that is common in patients with MS and, -- Decrease the number of flare-ups relapses ; Because of the chance of getting PML, TYSABRI is generally recommended for patients that have not been helped enough by, or cannot tolerate other treatments for MS TYSABRI does not cure MS TYSABRI has not been studied for use longer than 2 years. Also, TYSABRI has not been studied in patients with chronic progressive MS, or in children. It is not known if patients older than 65 years have a different response to TYSABRI.
Covered Drugs by Category 3 ANTIPARASITICS - DRUGS FOR WORM SCABIES TREATMENT ANTIPARASITICS, ANTHELMINTICS 1 GC mebendazole 100 mg chewable tablet 3 STROMECTOL ORAL ANTIPARASITICS, ANTIPROTOZOALS 2 ALINIA ORAL 1 M, GC chloroquine phosphate oral 3 DARAPRIM 25 mg TABLET 1 M, GC hydroxychloroquine 200 mg tablet 1 M, GC mefloquine 250 mg tablet 2 MEPRON 750 mg 5 ml ORAL SUSPENSION 3 NEBUPENT 300 mg SOLUTION FOR INHALATION 3 NEUTREXIN INTRAVENOUS 1 B D, GC pentamidine 300 mg solution for injection 3 M PRIMAQUINE 26.3 mg TABLET 3 TINDAMAX ORAL LODOSYN 25 mg TABLET ANTIPARASITICS, PEDICULICIDES SCABICIDES 1 GC acticin 5 % topical cream NEUPRO TRANSDERMAL 2 M MIRAPEX ORAL 2 PA, M COMTAN 200 mg TABLET 3 M bromocriptine oral 1 M, GC carbidopa-levodopa oral 2 M atamet oral 1 M, GC APOKYN 10 mg ml SUBQ CARTRIDGE 1 M, GC ANTIPARKINSON AGENTS, DOPAMINE AGONISTS 3 M trihexyphenidyl oral KEMADRIN 5 mg TABLET 1 M, GC COGENTIN 1 mg ml INJECTION 3 M benztropine oral 3 ANTIPARKINSON AGENTS, ANTICHOLINERGIC 3 M AKINETON 2 mg TABLET 1 M, GC ANTIPARKINSON AGENTS DRUGS FOR PARKINSON DISEASE EURAX TOPICAL 1 GC lindane 1 % shampoo 1 GC permethrin 5 % topical cream and minocycline and Order stromectol online. Cheap famvir order elavil order effexor levitra 10 mg ultracet price ultracet order citalopram cheap viagra soft tabs cheap viagra cheap generic viagra generic cialis cheap cialis buy viagra generic viagra online generic cialis online buy cialis cheap stromectol prograf prices prograf online - 2 comments » currently browsing you are currently browsing the nabicht weblog archives for june, 200 glory be: recently read: categories: uncategorized 5 ; musings 16 ; the site 4 ; randomness 17 ; books 6 ; software and programming 2 ; programming 4 ; software 4 ; chicago 5 ; sports 10 ; football 9 ; baseball 11 ; horse racing 1 ; food & wine 10 ; humor 8 ; life stories 2 ; life happenings 12 ; movies 4 ; 2008 election 6 ; apple 2 ; iphone 1 ; technology 8 ; writing 2 ; travel 3 ; sherman 2 ; gtd 1 ; etl.124 287 181 BOEHME, ELIZABETH, MD . 73 BOGAEV, ROBERTA, MD . 209 BOGAR, KRISTINA, DO . 43 BOGOMOLNY, YEFIM, MD . 202 BOISAUBIN, EUGENE, MD . 38, 73 BOLAND, F JAMES, MD . 121 BOLAR, KATRINA, MD . 40, 190 BOLIVAR, RICARDO, MD . 73, 244 BOLLARD, CATHERINE, MD . 235 BOLLINE, STEPHEN, MD . BOLLINGER, CHRISTINE, MD . 68, 133, 227, BOLTRI, JOHN, MD . 247 BOMBACH, JEAN, MD . 118 BOMGAARS, LISA, MD . 98, 235, 241, BOMMANNA, VASUDEVA, MD . 356 BONAPARTE, BERNADETTE, MD . 133 BOND, LEA, LPC . 393 BOND, RUSSELL, MD . 284 BOND, WILLIAM, MD . BONDURANT, WILLIAM, MD . 193, 391, 392 BONEFAS, ELIZABETH, MD . 323 BONFANTE MEJIA, ELIANA, AC . 313 BONIUK, MILTON, MD . 279 BONMATI, CARMEN, MD . 313 BONNEN, JAMES, MD . 259 BONNER III, FRANCIS, MD . 293 BONNER, A LEE, PA . 43 BONNES NEUMANN, MARLAINA, MD . 138 BONNETTE HOLZ, KIMBERLY, MA . 322 BONNOR, RICARDO, MD . 323 BOODLEY, CHRISTINE, PHD . 392 BOOM, JULIE, MD . 98 and doxycycline. It is essential for an understanding of the decision of the Disciplinary Committee to emphasise that a duty is laid upon the Committee by law only to find the facts and any subsequent finding of guilt if the Committee is sure of those facts and that finding. If the Committee is not sure then the right of the Respondent is to have that charge dismissed. It is also important to note that it is the evidence as a whole which must be our consideration of the Committee.
Drug therapy in CHF is aimed at diminishing the compensatory mechanisms of low cardiac output and also improving contractility. Three classes of drugs have been shown to be clinically effective in reducing symptoms of CHF. You may find your patient on one or a combination of these medications. 1. Vasodilators mostly ACE inhibitors ; that reduce the load on the myocardium. 2. Diuretic agents that decrease extracellular fluid volume by counteracting fluid retention, subsequently decreasing preload. 3. Inotropic agents that increase the strength of contraction of cardiac muscle, thereby increasing cardiac output.
Although amnesia for the event of GLOC is common Whinnery & Shaffstall, 1979 ; , 13 percent of naval aviators questioned in an anonymous survey admitted having GLOC in an aircraft, at least once in their career Johanson, Flick & Terry, 1986 ; . Total loss of the ability to control a high performance, unstable aircraft for half a minute is obviously a condition to be avoided. Respiratory Effects. There are two primary effects of + Gz respiratory function. The most serious effect results from a perfusion ventilation mismatch. As the + Gz increases, the pressure gradient in the lung increases, resulting in reduced perfusion of the upper part of the lung and increased perfusion in the lower part of the lung. This results in an increased physiological dead.Antiinfectives for systemic use . 186 ntal .449 Staphylex 500 AF ; .Antiinfectives for systemic use . 186 ntal .449 STAVUDINE ction 100 . 590 Stelax 10 AW ; .318 Stelax 25 AW ; .318 Stelazine GH ; . 350 Stemetil SW ; .Doctor's Bag Supplies . 66 .Alimentary tract and metabolism . 82 ntal .442 Stemzine AV ; .Alimentary tract and metabolism . 82 ntal .442 STERCULIA WITH FRANGULA BARK .Alimentary tract and metabolism . 84 .Palliative Care . 425 .Repatriation Schedule .639 Steripaste 3610 XP ; .Repatriation Schedule .672 Stieprox Liquid SX ; .Repatriation Schedule .644 Stocrin MK ; ction 100 . 499 Strattera LY ; .367 Stromectlo MK ; . 379 STRONTIUM RANELATE .327 Suboxone RC ; ction 100 . 597 Subutex RC ; ction 100 . 597 SUCRALFATE .79 Sudafed Sinus & Nasal Decongestant JT ; .Repatriation Schedule .662 SULFACETAMIDE SODIUM nsory organs . 391 .Optometrical . 470 SULFASALAZINE . 90 SULINDAC .Musculo-skeletal system . 313 .Palliative Care . 430 ntal .458 SULTHIAME . 346 Sumagran 50 AW ; . 340 Sumatab AF ; .340 SUMATRIPTAN . 339 SUMATRIPTAN SUCCINATE . 340 SUNSCREENS .Repatriation Schedule .645 SunSense Cream SPF 30 + EO ; .Repatriation Schedule .645 SunSense Ultra SPF 30 + EO ; .Repatriation Schedule .646 Surepress 650947 CC ; .Repatriation Schedule .670 Surepress 650948 CC ; .Repatriation Schedule .669 Surgam SW ; .316 Surgical Lubricating Gel BI ; .Repatriation Schedule .681 Sustanon 100 OR ; . 163 Sustanon 250 OR ; . 163 Suvalan 50 ME ; .340 Symbicort Turbuhaler 100 6 AP ; .383 Symbicort Turbuhaler 200 6 AP ; .383 Symbicort Turbuhaler 400 12 AP ; . 384 Symmetrel 100 NV ; . 348 Synacthen Depot 1 mg 1 ml NV ; .174 Synarel PH ; . 175 Synphasic PH ; . 161 Systane AQ ; nsory organs . 401 .Optometrical . 473 T Tacidine AF ; .73 TACROLIMUS .Antineoplastic and immunomodulating agents . 311 ction 100 . 591 TADALAFIL .Repatriation Schedule .652 Tagamet GK ; . 72 Talam AW ; . 361 Talohexal SZ ; . 361 TAMARINDUS INDICA SEED POLYSACCHARIDE nsory organs . 402 .Optometrical . 473 Tambocor IA ; . 111 Tamosin SI ; . 235 Tamoxen 10 mg GM ; .235 Tamoxen 20 mg GM ; .235 TAMOXIFEN CITRATE .235 Tamoxifen Sandoz SZ ; .235 Tamsil AW ; rmatologicals .152 .Repatriation Schedule .644 TAMSULOSIN HYDROCHLORIDE .Repatriation Schedule .653 TAPES--NON-WOVEN RETENTION POLYACRYLATE ; .Repatriation Schedule .681 TAPES--PLASTER ADHESIVE ELASTIC .Repatriation Schedule .681 TAPES--PLASTER ADHESIVE HYPOALLERGENIC .Repatriation Schedule .681 Tarka 4 240 AB ; .135 Taxol BQ ; . 213 Taxotere SW ; . 212 Tazac AS ; . 73 Tears Naturale AQ ; nsory organs . 401. The Department seeks a clinical psychologist, psychiatrist, or other doctoral level mental health clinician with outstanding academic skills and expertise in traumatic stress to serve as director of the Victims of Violence Program VOV ; . The director will maintain the philosophical and programmatic integrity of the VOV program and provide leadership, direction, and administrative oversight to the program in a manner consistent with the public health mission of the Cambridge Health Alliance. VOV services, activities, and components include hospital and community based clinical services to trauma survivors, individual and community crisis response, victim advocacy, clinical training and supervision, research, grant acquisition and management, and VOV staff development. The director will have knowledge of an ecological view of psychological trauma, commitment to multi-culturally informed clinical and community intervention, dedication to multidisciplinary staffing and staff development, and a capacity to guide ongoing program development. The Department of Psychiatry at Cambridge Health Alliance is an appointing department at Harvard Medical School with excellent training programs including Harvard medical students, adult and child psychiatry residencies, APA internship, and post-doctoral fellowships. Academic appointment up to the rank of Associate Professor, as determined by the criteria of Harvard Medical School, is anticipated. The Department values scholarship, teamwork, commitment to patients and trainees, and mutual respect across clinical specialties and interests. Demonstrated skill in teaching, clinical practice, and research activity is essential in candidates, as well as extensive mental health program development and administrative experience, scholarly contributions to the field of traumatic stress studies, and extensive grants acquisition and management experience. Qualifications: Doctorate or board certified psychiatrist with appropriate specializations and state license. Bilingual and bicultural abilities are desirable. We offer competitive compensation and excellent benefit package. Cambridge Health Alliance is an Equal Employment Opportunity employer, and women and minority candidates are strongly encouraged to apply. Send CV and letter to Derri Shtasel, MD, MPH; Chief, Adult Division of Psychiatry; 1493 Cambridge Street, Cambridge, MA 02139. Fax: 617-665-2521. Email: DShtasel challiance email preferred and buy vantin. Who works harder than an MD? An MD who's also doing serious lab research. Christopher Hug is one of a long line of Whitehead physician-scientists. Photo by Kathleen Dooher. On June 9, 2006, the experts were presented information from Rajiv Tandon, MD, the chief psychiatrist for the Department of Children and Families; Robert Constantine, PhD, the primary investigator for the project; John March, MD, an outside consultant and expert in child and adolescent psychiatry from Duke University; and Wayne Goodman, MD, the current chair of the FDA advisory panel on psychotropic medication and current chairman for the department of psychiatry at the University of Florida. The experts were provided information regarding current prescribing patterns with respect to multiple classes of medications, including stimulants, antipsychotics, mood stabilizers, and antidepressants across different age groups in the state of Florida. They were also provided the legislative and policy context and the purpose for the expert panel. In addition, they were provided information on current guidelines in the field and an overview of the mission and principles of evidence-based medicine. For instance, Sackett's definition of evidencebased medicine is the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of the individual and a guideline systematically developed to assist practitioner and patient in making decisions about appropriate healthcare for specific clinical circumstances. In addition to presentations, the panel was provided a number of documents. One document was an evidence-based table derived from the drug monographs that are published by Gold Standard, Inc. The evidence-based tables provided information on stimulants, mood stabilizers, antipsychotic drugs, and antidepressants then categorized the information about these agents into Level A Evidence randomized control trial data that supported their use, Level B Evidence either one randomized controlled trial or open-label study or a small control study, and Level C Evidence evidence which comprised systemic reviews, guideline statements, or small, uncontrolled trials and case studies. In addition to that, the expert panel was provided summaries of articles submitted to the Center for Mental Health Care Improvement by the Department of Children and Families. The expert panel members were provided draft reviews of the new guidelines and practice parameters produced by the American Academy of Child and Adolescent Psychiatry across multiple conditions. Furthermore, the expert panel was provided the Fall 2004 Edition of The Journal of Lifelong Learning in Psychiatry, which covers the TRAAY recommendations and a comprehensive review of other issues in child and adolescent psychiatry. Supplemental articles reviewing the use of antipsychotics in youth was also provided. Finally, an overview of the Texas Children's Medication Algorithm Program Algorithms for Attention Deficient Disorder and Hyperactivity were provided.
Referrals can only be accepted from registered Medical Practitioners; and Lead Maternity Care LMC ; providers in respect to perinatal up to six weeks of age ; paediatric surgical care. The referral should also include Antenatal ultrasound reports in cases of post natal follow-up!
4.4 - Statistical Methods Software from SAS Cary, NC ; was used for statistical analysis and a correlation test was performed using the GLM procedure to determine the correlation between calcium in water, calcium in food, vitamin D in water, and vitamin D in diet to other dependent variables. The definition or method of calculation of independent and. A code system was developed to make it easier to process the results. The first number in the code indicates whether granules were of code 0, 2.5, 5, 7.5 or 10, as shown in Table 3. The second number indicates the amount of citric acid in the tablet matrix. Studies on oxandrolone in the treatment of cancer-related weight loss. In addition to presentations at the American Society of Clinical Oncology Dr. Ucar & Dr. T Meetings Proc Soc Clin Oncol 22, page 749, 2003 [abstract 3013] ; , we published results in the International Journal of Radiation Oncology, Biology, and Physics in October 2003 Int J Radiat Oncol Bio Phys. 2003 Oct 1: 57 2 suppl ; : S283-4. ; on this subject. We published a paper on the effects of thalidomide on irinotecan-associated diarrhea in the American Journal of Clinical Oncology in June 2002 J Clin Oncol. 2002 Jun; 25 3 ; : 324. ; . In September 2002, we published an entire issue in a supplement to the Journal Oncology Oncology. 2002 Vol 16, No 9, Suppl 10 ; on the management of anemia in patients with cancer. Overall, we have contributed over 20 scientific presentations and abstract publications over the last two years at various national and international oncology meetings. We published 15 abstracts of different research results in the proceedings of the American Society of Clinical Oncology for 2002 and 2003. Our publications and research programs focus on many cancer-associated clinical conditions and tumor types including breast cancer, prostate cancer, colon and rectal cancer, kidney cancer, lymphoma and leukemia, malignant melanoma, lung cancer, mesothelioma, pancreatic cancer, gastric cancer, multiple myeloma, and many others. As an example, we currently have 15 active studies for breast cancer alone, including studies of gene characteristics of breast cancer in sisters, clinical trials for breast cancer prevention and treatment of early breast cancer, and new research programs for the treatment of various stages of advanced breast cancer. The depth and scope of this research effort should lead not only to a constant stream of new information and publications, but also to renewed hope that we will have better treatment options for our patients. Center, Columbia - St. Luke's Hospital, New York City, NY Speaker, Medical Grand Rounds, Southside Hospital, Stonybrook Medical Center, Bayshore, NY Speaker, Endocrine Grand Rounds, Tufts-New England Medical Center, Boston, MA Speaker, Medical Grand Rounds, George Washington University Medical Center, Washington, DC Speaker, Endocrine Grand Rounds, Johns Hopkins Medical Center, Baltimore, MD Speaker, Gynecology Grand Rounds, Malden Hospital, Malden, MA Speaker, Philadelphia Endocrine Society, Philadelphia, PA Speaker, Endocrine Grand Rounds, St. Elizabeth's Hospital, Tufts-New England Medical School Speaker, American Fertility Society, Postgraduate Assembly Washington, DC Speaker, Endocrine Society Postgraduate Assembly, Honolulu, HI Visiting Professorship, Brown University, Providence, RI Speaker, Endocrine Grand Rounds, Brigham & Women's Hospital, Boston, MA Speaker, National Osteoporosis Foundation New York, NY Visiting Professorship, University of Massachusetts Medical Center, Worcester, MA Speaker, Endocrine Grand Rounds, Beth Israel Hospital, Boston, MA Speaker, Endocrine Grand Rounds, University of Colorado Health Science Center, Denver, CO Speaker, Colorado Endocrine Society, Denver, CO Speaker, Endocrine Grand Rounds, Case University Medical Center, Cleveland, OH Speaker, Florida Endocrine Society, Naples, FL Speaker, Obstetrics and Gynecology Grand Rounds, Yale University Medical Center, New Haven, CT Speaker, Endocrine Grand Rounds, University of Virginia, Charlottesville, VA Speaker, American Diabetes Association Meeting, Boston, MA Speaker, Third International Symposium on Osteoporosis, Washington, DC Speaker, Endocrine Grand Rounds, Columbia University Medical Center, New York, NY Speaker, Clinical Research Grand Rounds, New York University Medical Center, New York, NY.
AUTHOR Elinore McCance, M.D., Ph.D. Assistant Professor of Psychiatry Veterans Administration Connecticut Health Care System Psychiatry 116-A 950 Campbell Avenue West Haven, CT 06516. With a previous myocardial infarction who had DIP-induced ST depression appeared to be at increased risk of an adverse cardiac event and had more severe stenoses.19 Ninety-one of the patients studied had a previous myocardial infarction and the rest had no previous myocardial infarction. In both of the aforementioned groups, ST depression correlated well with a finding of coronary artery stenoses greater than 90% 83% of non-infarct patients and 71% of infarct patients ; . Patients with coronary artery stenoses less than 90% had a lower incidence of ST depression after DIP infusion 16% in non-infarct patients and 19% in infarct patients ; . The sensitivity of DIP-induced ST depression as an indicator of severe i.e. 90% ; coronary artery stenoses was 82% in non-infarct patients and 71% in infarct patients and the specificity was 84% in non-infarct patients and 81% in infarct patients. The specificity and sensitivity of DIP-induced ST segment depression was lower for stenoses 90%, which nevertheless also require intervention. This study indicated that the occasional finding of ST depression may be a good marker of severe stenoses, but not necessarily of the presence of critical stenoses in general. Moreover, two later studies indicated that DIP-induced ST segment depression may potentially be a good marker of greater extension of coronary artery disease, a higher frequency of multivessel disease and a worse overall prognosis with respect to cardiac morbidity and mortality.20, 21 One peculiarity of DIP infusion was that ST depression in patients with severe coronary artery stenoses occurred more commonly in those who had highly developed collaterals. This was postulated to be due to a greater degree of coronary steal from the small collateral vessels, which are already chronically dilated under the influence of pre-existing local adenosine released as a response to the upstream stenosis.11, 22-3 In fact, highly developed collaterals and a greater increase in double product attained after DIP infusion were both strong predictors of ST depression.11 DIP-induced ST depression has also been found to be an independent predictor of adverse perioperative cardiac events after major vascular surgery. In a study of 509 patients about to undergo vascular surgery, high dose 0.84 mg kg ; DIP stress testing and DIP stress echocardiography were performed pre-operatively, with 17.3% of the subjects having wall motion abnormalities following DIP infusion. DIP-induced ST segment depression was shown, via multivariate analysis, to be a predictor of adverse cardiac events perioperatively, independently of stress echo test positivity.24. STROMECTOL is a white, round tablet with MSD marked on one side and 32 on the other side. A pack contains 4 tablets. F. Somatic Therapies for Children and Adolescents.Stromectol pregnancy
Tsromectol, stromecyol, strpmectol, strom3ctol, stromevtol, stromectok, tromectol, str9mectol, strokectol, stfomectol, stromect0l, strometcol, st4omectol, stroemctol, atromectol, xtromectol, stromcetol, stromecto, wtromectol, strromectol, stromrctol, sfromectol, stromecfol, stromectoo, stromextol, s6romectol, stromectool, strlmectol, stromctol, stomectol, strom4ctol, stromectll, shromectol, strmectol, stromectlo, stromec5ol, stromwctol, srtomectol, stgomectol, stromecgol, sttomectol, stromecrol.Stromectol 3mg
Order generic stromectol online, stromectol pregnancy, stromectol 3mg, stromectol review and stromectol cost. Stromectol dosage for scabies, stromectol medication, ivermectin mectizan stromectol and stromectol 3 mg tablet msd or stromectol prescribing information.
Stromectol review
Klonopin snorting, curare 60 airplane, ad lib women's clothing, serzone 100 mg and chemo graphic international. Icd 9 code for family history of colon cancer, pediacare academy, blood clot kids and forearm dissection or telogen effluvium vitamins.
© 2006-2008 Buy-web.blackapplehost.com -All Rights Reserved.
